جست‌وجوی استاد و پژوهشگر

• Oncology
• Urologic Oncology
• Geriatric Oncology
• +۳ مورد دیگر

Sumati V. Gupta, MD, is a tenured Associate Professor in the Division of Oncology, Department of Medicine at the University of Utah's Huntsman Cancer Institute (HCI). She specializes in genitourinary cancers (bladder, kidney, prostate, testicular) and geriatric oncology. Dr. Gupta serves as Medical Director of the Geriatric Oncology Clinic (GOAL) and co-Principal Investigator of the Total Cancer Care project at HCI. She also practices at the Salt Lake City Veteran Administration hospital, where she chairs the VISN-19 Interdisciplinary Cancer Committee. Education: MD: King Edward Memorial Hospital and Seth G.S. Medical College, Mumbai, India Residency: Internal Medicine, Nassau University Medical Center (SUNY Stony Brook) Fellowships: Geriatrics (Baylor College of Medicine), Medical Oncology (University of Utah) Research Focus: Her work investigates treatment resistance mechanisms in genitourinary cancers, clinical trial design for targeted therapies (e.g., FGFR/PARP inhibitors), and biomarker discovery. She leads studies on immunotherapy combinations, radiotherapeutic approaches, and real-world treatment patterns in urothelial/prostate cancers. Publications (Trends): Recent articles (2023-2025) emphasize phase II trials of novel agents (e.g., nivolumab, enfortumab vedotin), biomarker-driven therapies in FGFR-altered cancers, and real-world analyses of treatment attrition/disparities. Key themes include immunotherapy combinations, geriatric oncology considerations, and liquid biopsy applications. Leadership & Grants: Co-chairs the Genitourinary Cancers Research Interest Group (ORIEN consortium) and serves on HCI's Data Safety and Monitoring Committee. Active in multi-center trials (e.g., TROPHY-U-01, NEXT, RadSABR) funded by industry/academic partnerships. Clinical Teams: Leads the GOAL Clinic for older adults with cancer and collaborates with HCI's Experimental Therapeutics program. At VA hospitals, mentors residents/fellows and oversees genitourinary cancer research initiatives.

Merran Findlayمشاهده پروفایل

پژوهشگر ارشد

• Nutrition and Dietetics
• Clinical Nutrition
• Nutritional Science
• +۳ مورد دیگر

Dr. Merran Findlay is a Senior Research Fellow at UNSW Sydney and Clinical Associate Professor at The University of Sydney, specializing in cancer nutrition for over 25 years. She serves as Board Director for the Clinical Oncology Society of Australia and Australia and New Zealand Head and Neck Cancer Society. Her work bridges clinical practice with implementation science in nutrition assessment, malnutrition management, and value-based healthcare. Senior Research Fellow – Living Better With and After Cancer, Maridulu Budyari Gumal (SPHERE) Cancer Clinical Academic Group Clinical Appointments: Royal Prince Alfred Hospital, Chris O’Brien Lifehouse Leadership Roles: Co-founder of Implementation Science networks at UNSW and The University of Sydney Her research focuses on nutrition interventions in head and neck cancer, sarcopenia assessment, and evidence-based guideline implementation. She explores how nutritional status affects clinical outcomes, treatment complications, and healthcare costs through international multicenter studies and digital health innovations. Current research trends show strong emphasis on head and neck cancer nutrition , sarcopenia biomarkers , and implementation science for guideline adoption. Her work spans nutrition assessment , enteral nutrition , and health services research , with recent articles addressing AI integration in quality indicators and sarcopenia severity quantification. Dr. Findlay leads implementation programs like the Sydney Health Partners Implementation Science Program and conducts extensive audits including INFORM (International Nutrition Audit in Foregut Tumors). Her collaborative efforts involve developing CT-based sarcopenia metrics and optimizing nutrition counseling frequency during cancer treatment.

Carla Pradoمشاهده پروفایل

استاد

• Nutritional Assessment
• Clinical Nutrition
• Body Composition Analysis
• +۷ مورد دیگر

Dr. Carla Prado is a Distinguished University Professor and Canada Research Chair in Integrative Nutrition, Body Composition, and Energy Metabolism at the University of Alberta's Faculty of Agricultural, Life and Environmental Sciences. She leads the Human Nutrition Research Unit, a globally recognized facility for body composition and energy metabolism assessments. Her research focuses on nutritional status evaluation in chronic diseases, particularly cancer, and developing precision nutrition interventions to optimize muscle health. Dr. Prado has authored over 200 peer-reviewed articles and co-authored the award-winning High Protein Cookbook , which guides cancer patients in dietary choices. She holds prestigious honors including Fellow of the Canadian Academy of Health Sciences and Clarivate's Highly Cited Researcher distinction (top 1%). Education and Training: PhD in Nutrition & Metabolism (University of Alberta) Postdoctoral Fellowships: NIDDK (NIH), Cross Cancer Institute (U of Alberta) Visiting Professorships: University of Hawaii Cancer Center, Newcastle University (UK) Research Interests: Dr. Prado investigates body composition abnormalities in chronic illnesses, with emphasis on cancer cachexia, sarcopenia, and malnutrition. Her work bridges clinical practice and research, emphasizing translational strategies for personalized nutrition. Key areas include: Muscle health biomarkers Protein intake optimization Imaging-based diagnostics Prehabilitation strategies Awards: Canada’s Top 40 Under 40 (2015) Clarivate Highly Cited Researcher (2024) Member, Royal Society of Canada College of New Scholars (2020) Lab Activities: The PradoLab develops clinical tools and educational resources, including: Body composition educational modules (ANHI) Clinical decision-support algorithms Public health campaigns on muscle health

• Cancer Biology
• Immunology
• Autophagy
• +۳ مورد دیگر

Kristine Pettersen is an affiliated researcher at the Norwegian University of Science and Technology (NTNU), specializing in cancer biology and immunology. Her work focuses on the interplay between cancer cells, immune cells, and muscle cells, particularly in the context of cancer cachexia—a severe muscle-wasting syndrome. She investigates autophagy's role in tumor immunity and cachexia mechanisms, aiming to identify diagnostic markers and therapeutic strategies. Education: Dr. Philos. in Molecular Medicine (2016, NTNU). Research Group: Autophagy and Tumor Immunity. Teaching: HBIOT2031 - Molecular Diagnostics and Applied Bioinformatics. Key research themes include tumor microenvironment dynamics, systemic effects of cancer, and targeted interventions for cachexia. Her outreach includes public lectures on cancer-related muscle loss and its implications. Scientific contributions span over 10 peer-reviewed articles, highlighting her expertise in IL-6 signaling, autophagy regulation, and translational cancer research. Awards include the Cancer Society Prize for Young Cancer Researchers (2023).

Ruben Vazquez Uribeمشاهده پروفایل

پژوهشگر

• Bacterial Synthetic Biology
• Microbiome Engineering
• Advanced Microbiome Therapeutics
• +۱۲ مورد دیگر

Ruben Vazquez Uribe is a Co-Principal Investigator at the Bacterial Synthetic Biology Section, Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark (DTU). His research is centered on developing programmable microbial therapeutics for metabolic and inflammatory diseases, leveraging synthetic biology and microbiome engineering. Research Interests: His work spans bacterial synthetic biology, microbiome modulation, engineered probiotics, oral delivery of peptides, and AI applications in drug discovery. He focuses on conditions like metabolic diseases, cancer cachexia, and NAFLD, aiming to develop living microbial medicines with precise therapeutic functions. The recent articles highlight a strong trend toward advanced microbiome therapeutics , combining synthetic biology with gut microbiome manipulation. Key themes include engineering Saccharomyces boulardii and Escherichia coli for enhanced delivery and immunomodulation, using AI to accelerate screening, and applying metagenomics to isolate novel gut microbes. These efforts reflect a multidisciplinary approach integrating biotechnology, computational methods, and translational medicine. Scientific Contributions: Co-PI in multiple long-term research projects since 2015. Supervisor for four active PhD projects on microbiome therapeutics and cancer. Host and guest lecturer in national and international academic events. Advising and Grants: He actively supervises PhD students across projects related to microbiome synthetic biology and personalized medicine. He is involved in research funded by the Novo Nordisk Foundation, contributing to high-impact publications and innovative therapeutic platforms. His team collaborates widely across Europe, focusing on translational microbiome applications. Labs and Teams: He leads research within the Bacterial Synthetic Biology Section at DTU Biosustain, a center dedicated to sustainable biotechnology. The team specializes in engineering microbial consortia, developing synthetic genetic circuits, and translating findings into clinical applications.

Marina Mourtzakisمشاهده پروفایل

دانشیار مدعو

• Sarcopenia
• Body Composition Analysis
• Muscle Physiology
• +۵ مورد دیگر

Marina Mourtzakis is an Adjunct Associate Professor in the Department of Kinesiology at McMaster University. Her academic work focuses on the intersection of body composition analysis, muscle physiology, and clinical applications across various patient populations including those with cancer, critical illness, and metabolic disorders. Dr. Mourtzakis's research interests primarily center around: Sarcopenia assessment and implications in clinical populations Advanced body composition analysis techniques, particularly using ultrasound and CT imaging The relationship between muscle quality, adipose tissue distribution, and health outcomes Nutritional implications of body composition changes in disease states Development of standardized methodologies for body composition research Her publication record demonstrates a strong focus on translating body composition research into clinical practice. Recent work has emphasized methodological standardization, novel biomarkers for cancer prognosis, reliable ultrasound protocols, and understanding the complex relationship between body composition and disease outcomes across multiple disciplines including oncology, nephrology, cardiology, and critical care medicine. Dr. Mourtzakis has contributed significantly to guidance documents including the Global Leadership Initiative on Malnutrition (GLIM) criteria for malnutrition diagnosis in critically ill patients. Her collaborative work spans multiple clinical domains, with particular emphasis on developing practical tools and standards that can be implemented in both research and clinical settings to improve patient assessment and outcomes.

• Cancer Cachexia
• Metabolism and Cancer
• Adipose Tissue and Skeletal Muscle Physiology

Serkan Kır is an Assistant Professor in the Department of Molecular Biology and Genetics at Koç University, Turkey. His research focuses on the molecular mechanisms underlying cancer cachexia, muscle wasting, and metabolic dysregulation in tumor-host interactions. Education: PhD, UT Southwestern Medical Center (2011) Bachelor’s, Bilkent University (2006) His work investigates: Role of interleukin-6 family cytokines in muscle degradation EDA2R-NIK signaling in skeletal muscle pathophysiology Tumor-derived ligands regulating MEK activation Adipose tissue thermogenesis and fibroblast growth factors PTHrP and EGFR interactions in cachexia models Recent publications highlight advancements in targeting metabolic reprogramming and signaling pathways for cachexia therapies. Key article trends include cancer metabolism, muscle physiology, and cytokine-driven wasting mechanisms.

Anna Beaudryمشاهده پروفایل

استادیار

• Cancer Cachexia
• Exercise Physiology
• Sports Medicine
• +۳ مورد دیگر

Dr. Anna Beaudry serves as Assistant Professor of Biology and Exercise Science at Roberts University, where she teaches highly-rated courses as evidenced by student reviews describing her lectures as "amazing" and "instructional." A Certified Exercise Physiologist (ACSM-EP) and NSCA-Certified Personal Trainer, she maintains active membership in the American College of Sports Medicine and National Strength and Conditioning Association while applying clinical expertise with cardiac, pulmonary, and neurologic populations. Her academic foundation includes: Ph.D. in Exercise and Nutrition Sciences from Baylor University B.S. in Sports Medicine and Exercise Science from Mercyhurst University Dr. Beaudry's research program integrates molecular oncology with sports biomechanics, focusing on cardiac dysfunction mechanisms in cancer cachexia and injury prevention in athletic populations. Her work examines physiological pathways to improve cancer patient quality of life while analyzing pitching mechanics, sex-specific injury patterns, and nutritional interventions for athletes. This dual focus bridges preclinical models with direct clinical applications across diverse patient groups. Analysis of her 2022-2024 publications reveals two dominant research streams: cancer cachexia investigations covering obesity interactions, leucine supplementation, and cardiac remodeling; and sports orthopedics studies on baseball pitching styles, ulnar collateral ligament injuries, and female athlete health. This demonstrates consistent translational impact from molecular mechanisms to practical clinical solutions. At Roberts University, she directs research in the Law Laboratory where preclinical cancer cachexia models inform therapeutic development. Her community engagement extends beyond academia through church participation and outdoor activities, reflecting her philosophy that "health is real wealth" as quoted by Gandhi on her faculty profile.

Reyhaneh Farghadaniمشاهده پروفایل

مدرس

• Cancer Drug Discovery
• Breast Cancer Therapy
• Molecular Oncology
• +۴ مورد دیگر

Dr. Reyhaneh Farghadani is an Assistant Lecturer at the Jeffrey Cheah School of Medicine and Health Sciences, Monash University, Malaysia, and affiliated with the Victorian Heart Institute (VHI). She holds a PhD in Molecular Medicine from the University of Malaya (2019) and has expertise in anti-cancer drug discovery, particularly focusing on breast cancer and natural products. Her work contributes to Sustainable Development Goals related to health and well-being. Education: PhD in Molecular Medicine, University of Malaya (2015–2019) MSc in Biotechnology, University of Technology Malaysia (2011–2013) BSc in Cellular & Molecular Biology, Shahrekord University (2005–2009) Research Interests: Molecular oncology and cancer drug discovery Anti-cancer mechanisms of natural products Immunotherapy and tumor microenvironment modulation Triple-negative breast cancer (TNBC) therapy Her research emphasizes novel compounds, such as Schiff base derivatives, and explores polyphenols' role in cancer treatment. Teaching Commitments: NUT1021 - Fundamentals of Human Nutrition MED 2100/2200 - Student Project Cases (SPC) MED 5101 - Scholarly Intensive Placement (SIP) BRM5011 - Foundations for Medical Biotechnology Research Trends: Recent publications focus on immunotherapy strategies (e.g., c-MET targeting), natural product-based drug development, and analyzing clinical trial outcomes for therapies like TECENTRIQ® and OPDIVO® in TNBC and hepatocellular carcinoma. Advising & Grants: Supervised projects on cachexia in breast cancer, ABC transporters in cancer therapy, and resveratrol's chemosensitizing role. Peer-reviewed for journals like Heliyon . Labs/Teams: Affiliated with the Victorian Heart Institute, contributing to collaborative cancer research initiatives.

• Exercise Gerontology
• Exercise Oncology
• Cancer Rehabilitation
• +۳ مورد دیگر

Professor Dennis Taaffe is a leading academic in Exercise Gerontology and Exercise Oncology at Edith Cowan University (ECU), affiliated with the School of Medical and Health Sciences and the Exercise Medicine Research Institute. He holds a prestigious Vice-Chancellor’s Professorial Research Fellowship. His academic journey includes a PhD from the University of Oregon, postdoctoral training at Stanford University, and additional qualifications such as a DSc from Charles Sturt University and an MPH in epidemiology from the University of Hawai'i. Professor Taaffe’s research focuses on the intersection of exercise, aging, and cancer, with a particular emphasis on improving treatment outcomes through exercise interventions. His work spans clinical trials, systematic reviews, and meta-analyses examining the effects of exercise on muscle function, inflammation, and cancer progression. Notable contributions include studies on exercise’s role in mitigating side effects of androgen deprivation therapy for prostate cancer and its impact on tumor biology. Key achievements include awards for clinical research excellence and teaching, along with recognition from the American College of Sports Medicine and Exercise and Sports Science Australia. His research has been published in high-impact journals such as JAMA Network Open , Journal of the National Cancer Institute , and British Journal of Sports Medicine . Professor Taaffe leads the Exercise and Gastrointestinal Cancers Research Group and collaborates on national and international projects, including clinical trials like the ERADICATE study (examining exercise and radiation therapy efficacy) and the EXPAN trial (focusing on pancreatic cancer prehabilitation). His work bridges clinical practice and research, aiming to integrate exercise as a cornerstone of cancer care.

Janelle Ayresمشاهده پروفایل

استاد

• Immunology
• Microbiology
• Host-Pathogen Interactions
• +۶ مورد دیگر

Janelle Ayres, PhD, is a Professor and Laboratory Head at the Salk Institute for Biological Studies. Her primary affiliations include the Gene Expression Laboratory, Molecular and Systems Physiology Laboratory, and the NOMIS Center for Immunobiology and Microbial Pathogenesis. She is also a Howard Hughes Medical Institute Investigator and holds the Salk Institute Legacy Chair. Ayres completed her BA in Molecular & Cell Biology at UC Berkeley, her PhD in Microbiology & Immunology at Stanford University, and a postdoctoral fellowship at UC Berkeley. Her research focuses on understanding how host physiologies and microbial interactions promote health, particularly through disease tolerance mechanisms. She discovered the co-operative defense system, which allows hosts to survive infections without eliminating pathogens. This work challenges traditional antibiotic-dependent approaches and opens avenues for therapies targeting host-pathogen cooperation. Key areas include metabolic defenses, immunometabolism, and microbiome-driven health promotion. Ayres' recent studies highlight drugs like fluoxetine (Prozac) as potential sepsis treatments by enhancing host tolerance. Her work also explores how pathogens evolve into symbiotic relationships with hosts, reducing infection threats. Major awards include the NIH Pioneer Award (2018), Blavatnik National Award (2018), and HHMI Investigator status (2024). Her research spans interdisciplinary collaborations, including studies on cancer cachexia, microbiome-metabolome interactions in colorectal cancer, and age-related sepsis defenses. Ayres' lab integrates evolutionary theory, systems biology, and clinical insights to redefine strategies for managing infections and promoting healthy aging.

• Cancer Cachexia
• Palliative Care
• Brain Tumors
• +۱ مورد دیگر

Tora Skeidsvoll Solheim is a Professor and Consultant in Medical and Radiation Oncology at St. Olav's Hospital, affiliated with NTNU's Department of Clinical and Molecular Medicine. Her clinical research focuses on cancer cachexia pathophysiology, classification, and therapeutic interventions. She leads studies on nutritional support, palliative care models, and glioblastoma treatments. Her work appears in high-impact journals including the Journal of Cachexia, Sarcopenia and Muscle, and BMC Palliative Care. Solheim contributes to European clinical guidelines through ESPEN and ESMO, and coordinates multinational trials on cachexia management.

• Skeletal Muscle Biology
• Metabolic Disorders
• Cancer Cachexia
• +۳ مورد دیگر

Nicoletta Filigheddu is an Associate Professor at the University of Eastern Piedmont Amedeo Avogadro's Department of Translational Medicine. Her research focuses on skeletal muscle biology, metabolic disorders, and molecular pathways underlying muscle wasting in aging and disease. She has led projects investigating vitamin D's role in muscle preservation, dietary interventions for metabolic dysfunction, and natural compounds to counteract sarcopenia. Affiliation: Department of Translational Medicine Key Collaborations: Projects with Fondazione Cariplo, MIUR, and interdisciplinary teams Her work integrates cellular and molecular biology with translational medicine, addressing conditions like cancer cachexia, sarcopenia, and age-related osteoporosis. Recent studies explore the anti-inflammatory effects of horsetail extract and the metabolic impacts of ketogenic diets. Research outputs span 68 peer-reviewed articles, with recent emphasis on calcium signaling in neurodegenerative diseases, mitochondrial dysfunction, and vitamin D's dual roles in muscle health. Grants include leadership of projects like 'WESTERNAGE' (combating muscle wasting via natural compounds) and 'FFABR 2017' (basic research funding).

• Medical Oncology
• Breast Cancer
• Tumor Immune Microenvironment
• +۳ مورد دیگر

Kathleen Fenn, MD, is an Assistant Professor of Medicine (Medical Oncology) at Yale School of Medicine. She specializes in early-stage HR-positive/HER2-positive breast cancers and focuses on the interaction between the immune system and tumors. Dr. Fenn is affiliated with Yale Cancer Center, Yale Medicine, and Smilow Cancer Hospital, where she provides clinical care. She is a member of the T32 Cancer Biology Training Program, contributing to cancer research workforce development. Dr. Fenn completed her MD at Yale School of Medicine (2014) and earned a BS in Molecular Biophysics & Biochemistry from Yale University. She pursued internship (2015), residency (2017), and fellowship (2020) in Internal Medicine, Hematology, and Oncology at Columbia University Irving Medical Center. Her clinical expertise includes medical oncology and hematology, with presentations at national conferences like the San Antonio Breast Cancer Symposium. Dr. Fenn leads a Phase III clinical trial (LoTam) as Principal Investigator and participates as Sub-Investigator in trials involving Pembrolizumab/Brentuximab Vedotin, Prostate Cancer genomic risk stratification, and Pancreatic Cancer treatment modalities. These trials reflect her commitment to advancing evidence-based therapies for solid tumors and hematologic malignancies. She collaborates with interdisciplinary teams at Smilow Cancer Hospital locations in Trumbull, Fairfield, and Bridgeport, emphasizing patient-centered care and translational research. Dr. Fenn’s academic profile includes affiliations with Internal Medicine, Medical Oncology, and Hematology departments at Yale School of Medicine.

Norma Frizzellمشاهده پروفایل

استاد

• Mitochondrial Metabolism
• Protein Modification
• Redox Biology
• +۵ مورد دیگر

Norma Frizzell, Ph.D., is a Professor in the Department of Pharmacology, Physiology & Neuroscience at the University of South Carolina School of Medicine. Her research focuses on the chemical modification of proteins by mitochondrial metabolites, particularly the non-enzymatic succination of cysteine residues by fumarate. She has made significant contributions to understanding how metabolic alterations in mitochondrial disorders like Leigh Syndrome and in diabetes lead to pathological protein modifications. B.Sc. in Biochemistry, Queen's University of Belfast, Northern Ireland Ph.D. in Biochemistry, Queen's University of Belfast, Northern Ireland Postdoctoral Training, University of Ulster and University of South Carolina Her work investigates the role of fumarate and protein succination in mitochondrial encephalopathies and metabolic diseases. She was the first to document increased brainstem and olfactory bulb succination in a murine model of Leigh Syndrome and to study succination of adipocyte proteins in diabetes. Her research bridges redox biology, metabolism, and disease mechanisms, with implications for therapeutic interventions in neurodegenerative and metabolic disorders. Recent publications reveal her focus on mitochondrial stress, metabolic crosstalk, and the impact of oncometabolites. Her work spans proteomics, cell signaling, and disease models, with studies in diabetes, cancer, neuroinflammation, and infectious disease. She frequently collaborates on chemoproteomic and redox biology projects. Scientific contributions include: Pioneering research on protein succination in diabetes Discovery of mitochondrial-ER stress links via succination Elucidation of fumarate’s role in neurodegeneration and tumor suppression Development of chemoproteomic methods to profile oncometabolites Dr. Frizzell has mentored researchers such as Dr. Gerardo Piroli and collaborates with interdisciplinary teams. Her work is supported by ongoing publications in high-impact journals, indicating active research and funding. She has no listed awards in the provided text, but her publication record in journals like Nature , Redox Biology , and Cancer Research underscores her scientific impact. She leads a research laboratory focused on the succinated proteome and metabolic signaling, contributing to both basic science and translational applications in metabolic and neurological diseases.